
DarioHealth (DRIO) Stock Forecast & Price Target
DarioHealth (DRIO) Analyst Ratings
Bulls say
DarioHealth is a promising digital therapeutics company with a strong focus on delivering user experiences, longer sustained engagement, and stronger clinical outcomes at affordable prices, which translates to the highest return on investment in the industry. The company has a solid track record of growth, with a 30% reduction in adjusted operating losses expected in 2026 and cash flow breakeven by mid-2027. While there are risks associated with the high demand for HCIT and potential customer losses, DarioHealth's pipeline and current access to covered lives position them well for success in the enterprise market.
Bears say
DarioHealth is seeing strong growth on the B2B2C side, with 10 new accounts added in 1Q26 and a pipeline expansion to $127M. However, the company's target of breakeven by mid-'27 may be overly ambitious in light of potential changes in materiality of factors within the ESG space, as well as increasing competition in the DTx market. The company may need to reassess its strategy and focus on sustainable growth rather than short-term financial goals.
This aggregate rating is based on analysts' research of DarioHealth and is not a guaranteed prediction by Public.com or investment advice.
DarioHealth (DRIO) Analyst Forecast & Price Prediction
Start investing in DarioHealth (DRIO)
Order type
Buy in
Order amount
Est. shares
0 shares